Overview

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu Cancer Institute & Hospital

Treatments:

Cisplatin
Docetaxel
Endostar protein
Endostatins